Agios Pharmaceuticals Insider Buys 3,000 Shares

Sarah Gheuens, the Chief Medical Officer at Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), bought 3,000 shares of the company. The transaction took place on June 18, 2026. The purchase was not part of a pre-arranged trading plan.

Other Institutional Activity in Agios Pharmaceuticals

BlackRock, Inc. increased its holdings in Agios Pharmaceuticals, adding 519,528 shares to reach a total of 5,754,957 shares valued at approximately $194.7 million, marking a 9.9% increase. Farallon Capital Management LLC also grew its position by 524,495 shares, ending with 5,684,000 shares worth around $192.3 million, a 10.2% increase. State Street Corp added 256,734 shares, resulting in 3,364,879 shares valued at about $113.7 million, an 8.3% increase. On the other hand, Armistice Capital, LLC reduced its position by 320,000 shares, leaving it with 2,716,000 shares valued at approximately $91.9 million, a 10.5% decrease.

Agios Pharmaceuticals, Inc. Stock Up 3.8%

Shares of Agios Pharmaceuticals traded near $35.47 on Wednesday. The company, which focuses on biotechnology, has a market capitalization of roughly $2.09 billion. Agios isn't currently profitable, so it doesn't have a meaningful P/E ratio. The stock's 52-week range is between $22.24 and $46.00, with a 50-day moving average of $29.03 and a 200-day moving average of $31.74. Agios maintains a strong financial position with a current ratio of 14.19 and a quick ratio of 12.80.

Recent Earnings

Agios Pharmaceuticals reported revenue of $66.05 million, with a modest growth of 1.38%. The company is not yet profitable, reflected in its negative return on equity of -32.8%. The next earnings report is expected on July 30, 2026.

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

In addition to Sarah Gheuens, several other insiders also made purchases on June 18, 2026. Jacqualyn Fouse, David Scadden, Cynthia Smith, Jay Backstrom, and Rahul Ballal each acquired shares, with David Scadden and Cynthia Smith buying 2,816 shares each, while the others purchased 14,950 shares.

Analysts Set New Price Targets

On June 11, 2026, JP Morgan maintained its hold rating on Agios Pharmaceuticals with a price target of $31. Previously, B of A Securities had maintained a buy rating with a $40 target on May 29. The consensus among analysts is a buy, with an average target price of $40.75 based on 8 opinions.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company specializing in the development of medicines targeting cellular metabolism. Its primary product, PYRUKYND, is used to treat hemolytic anemias in adults with pyruvate kinase deficiency and is under trial for sickle cell disease. The company is also working on other treatments for various blood disorders and genetic diseases.

Bottom Line

Insider buying at Agios Pharmaceuticals by Sarah Gheuens and others highlights confidence in the company's future. Investors follow insider transactions for potential insights, though these trades are reported after the fact. Agios Pharmaceuticals remains a key player in the biotechnology sector, with ongoing developments in its treatment pipeline and active institutional interest.